Alnylam Assist™: Patient Support Program

Hi, I'm Natalie:
Your patient's local Case Manager

I'm here to support patients throughout their Alnylam treatment experience. I am specifically assigned to work with certain patients on questions they may have about Alnylam Assist™ and AMVUTTRA® (vutrisiran).

1-833-256-2748

Monday - Friday, 8am - 6pm

Options for Getting Started

In order to make the process convenient for your patients, Alnylam Assist™ provides 3 separate options for initiating and completing the Start Form.

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Complete and submit the electronic Start
Form with your patient

Get Started

Alnylam assist® Start Form - To Print and Fax

Print, complete with your patient, and fax
the Start Form to 1-833-256-2747

Download

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

Fill out your sections of the Start Form
and email to patient to complete
via DocuSign

Begin Start Form

DocuSign Instructions ›

What Services Does Alnylam Assist™ Offer to Patients?

Alnylam Assist™ offers support services to help your patients access Alnylam products.

Alnylam Assist® - Questions Icon

Find answers to other

Frequently Asked Questions ›

IMPORTANT SAFETY INFORMATION

Reduced Serum Vitamin A Levels and Recommended Supplementation
AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions
The most common adverse reactions that occurred in patients treated with AMVUTTRA were arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

INDICATION

AMVUTTRA® (vutrisiran) is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.